SCA
CORT icon

STALEY CAPITAL ADVISERS’s Corcept Therapeutics CORT Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,764
Closed -$230K – 193
2025
Q3 		$230K Hold
2,764
– – 0.01% 176
2025
Q2 		$203K Buy
2,764
+590
+27% +$42.8K 0.01% 182
2025
Q1 		$248K Buy
+2,174
New +$132K 0.01% 169

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

STALEY CAPITAL ADVISERS's CORT Position: Q4 2025 in Review

STALEY CAPITAL ADVISERS sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 2,764 shares — an estimated $230K sold.

STALEY CAPITAL ADVISERS first reported a position in CORT in Q1 2025 and held it in 3 quarters. The position peaked at $248K in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • STALEY CAPITAL ADVISERS reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • STALEY CAPITAL ADVISERS sold 2,764 Corcept Therapeutics shares in Q4 2025, an estimated $230K.
  • STALEY CAPITAL ADVISERS first reported a position in Corcept Therapeutics in Q1 2025 and held it in 3 quarters.
  • STALEY CAPITAL ADVISERS's Corcept Therapeutics position peaked at $248K in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q4 2025, filed 5 Feb 2026.